Community discussions
We’re proud to announce the signing of our licensing agreement with Kwangdong Pharmaceutical—a top five pharmaceutical and healthcare company in Korea—for our first regional gene therapy partnership.
This collaboration underscores Ocugen’s commitment to expanding access to innovative treatments worldwide and includes:
Upfront and near-term milestone payments totaling $7.5 million
25% royalties on net sales
$1.5 million for every $15 million of sales in Korea—that can potentially
add up to $180 million or more in the first 10 years of commercialization
Together with Kwangdong, we aim to bring hope to the estimated 7,000 individuals living with RP in Korea.
This is a win-win partnership for Ocugen and Kwangdong that aligns with our mission and business development strategy.
Under the future agreement, Ocugen said it will receive up to $11 million in upfront and near-term milestone payments, plus $1 million in sales milestones for every $15 million in Korean sales.
